Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Edwards Lifesciences reported better-than-expected fourth-quarter sales and in-line profit. But EW stock fell in late trades Tuesday.

Edwards Lifesciences Dips On In-Line Profit, Narrow Sales Beat

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30; adjusted EPS of $2.51 Completed enrollment early in PROGRESS pivotal trial, studying.

Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

Integer Holdings

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?

ITGR or EW: Which Is the Better Value Stock Right Now?

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate.

Edwards' EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Beyond analysts' top -and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Stay Ahead of the Game With Edwards Lifesciences (EW) Q4 Earnings: Wall Street's Insights on Key Metrics

Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Edwards Lifesciences (EW): Can Its 6.2% Jump Turn into More Strength?

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwar.

Edwards Lifesciences to Host Earnings Conference Call on February 6, 2024

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?

ITGR vs. EW: Which Stock Is the Better Value Option?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences is down 3.10% over the last year but I am bullish due to its optimistic outlook and growth initiatives. The company is committed to its shareholders through EPS growth and share buyback program. EW stock is undervalued with a double-digit upside potential, warranting a buy rating.

Edwards Lifesciences: Undervalued With A Substantial Upside Potential

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived ve.

Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

On December 7, 2024, Edwards Lifesciences EW Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its plans to spin-off its Critical Care unit into an independent listed company to focus on structural heart disease (SHD) business.

Edwards Lifesciences To Spin-Off Critical Care Unit In 2024

Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.

Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook

Edwards Lifesciences said on Thursday it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business.

Edwards Lifesciences to spin off critical care unit to focus on heart devices

Edwards Lifesciences Corp.'s stock EW, +0.93% rose 1.9% in premarket trading Thursday after it said it plans to form an independent company out of its Critical Care unit in a tax-free spinoff transaction by the end of 2024. The business is expected to generate about $905 million of sales in 2023.

Edwards Lifesciences to spin off Critical Care unit, sets $1B stock buyback

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will discuss the company's sharpened focus and strategy for longer-term growth, provide an update on its technology pipeline and share financial guidance1 today during its annual investor conference. Highlights of today's conference include: Expecting early completion of enrollment in PROGRESS, studying moderate AS patients, in early 2024 Expecting data from EARLY TAVR, studying severe asymptomatic AS patients, at TCT.

Edwards Lifesciences Outlines Growth Strategy at Annual Investor Conference

Boston Scientific

Medtronic

Ozempic could make some medical devices less necessary than before. If that happens, it would lead to lower revenue for the device makers.

Could Ozempic Harm These 3 Medical Device Stocks?

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Edwards Lifesciences (EW) Up 6.8% Since Last Earnings Report: Can It Continue?

Agilent Technologies

Albemarle

Carrier Global

Celsius Holdings

Campbell Soup

Home Depot

Keurig Dr Pepper Inc

Kimberly-Clark

ResMed

Stocks that are under-earning and trading below historical averages may benefit if inflation continues to cool, according to Wolfe Research.

These 10 Stocks Are Laggards. They May Be Too Cheap To Ignore.

Edwards Lifesciences delivered 10.9% organic revenue growth and reiterated full-year guidance, boosting confidence in their $10 billion revenue opportunity by 2028. Clinical trial updates show excellent survival rates for patients receiving the SAPIEN 3 valve, reinforcing Edwards Lifesciences' dominance in the structural heart area. Q3 results met expectations, with a 10.9% organic revenue growth, and the company maintains a strong balance sheet and aims to achieve $10 billion in revenue by 2028.

Edwards Lifesciences Q3: Clinical Trial Updates Impress

The maker of medical devices posted third-quarter results that broadly met analyst expectations. That wasn't the reason for the resulting investor sell-off, however.

Why Edwards Lifesciences Stock Plummeted Today

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (TEER) therapies, as well as one-year results from the CLASP IID registry. The studies confirm the clinical and quality-of-life benefits of mitral regurgitation (MR) reduction with the PASCAL system in a broad population of patients with degenerative mitral regurgitation (DMR).

CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION

SAN FRANCISCO , Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization. The outcomes for the first 150 patients of the TRISCEND II trial achieved the primary safety endpoint at 30 days and both co-primary effectiveness endpoints at six months, demonstrating superiority to OMT alone.

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION

News for Edwards Lifesciences Stock (EW)